LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
23.3.2021 13:00:00 CET | LEO Pharma | Press release

Ballerup, Denmark, March 23, 2021.
LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%)
Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market share. Total revenue declined 1.8% when excluding discontinued or divested products. This was offset by the impact of coronavirus lockdowns, generics in Europe and further price pressure in the US.
- Revenue of Enstilar® increased 3% (+10% in Europe) to DKK 1,125 million, compared to topical market declining 2%
- Revenue of Kyntheum® increased 40% to DKK 467 million compared to market growth of biologics for psoriasis of 16%
Strategic projects progressed as planned while LEO Pharma ensured business continuity
In response to the coronavirus pandemic, LEO Pharma successfully implemented a plan to ensure safety and corporate responsibility, continuity of supply, and continuity of strategic projects.
- Supply chain and clinical trials continued uninterrupted
- Introduced 2030 strategy and aligned its organization to meet the ambitions of continuous growth and launch of a first- or best-in-class medicine every 2-3 years
- Divested non-core assets to Cheplapharm
- Committed to the Paris Agreement on climate change by setting a science-based target with a program to reduce CO2 emissions by 50% by 2030.
- Established a GLT with key focus on diversity in gender (50/50), age and competences with focus on delivering performance
R&D pipeline advanced significantly
LEO Pharma’s R&D pipeline progressed and achieved several important milestones, in line with the 2030 strategy.
- Phase 3 results for tralokinumab in atopic dermatitis enabled FDA and EMA filling. Anticipated global launch in 2021
- Announced positive results of a phase 2b dose-finding study with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema
- New partnership with Oneness Biotech and Microbio Shanghai for atopic dermatitis and asthma
- Added an IL-17 small molecule modulator for treatment of psoriasis from own R&D to the pipeline
EBIT: Operating loss better than financial guidance
Despite a decline in revenue and continued heavy investments in the R&D pipeline and global launches, LEO Pharma exceeded its profitability targets through building and agile, simple and efficient organization and a gain from the divestment of non-core products to Cheplapharm.
Focus in 2021 on launch of tralokinumab, further R&D investments and implementation of lean operating model
In 2021, LEO Pharma will continue to move forward towards realizing its 2030 ambitions by the anticipated launch of tralokinumab and continued investments in clinical development and focus on growth and profitability for the established portfolio. Revenue is expected to remain flat affected by the divesture of non-core products, while the operating loss will grow due to the investment in LEO Pharma’s future products.
Catherine Mazzacco, CEO and President of LEO Pharma commented:
“2020 was an eventful year for all, but I am happy to say that LEO Pharma delivered significant strategic progress and solid financial performance. Our rapid response to coronavirus helped us keep our promise to patients, while meeting our operating profit goals and advancing our strategic projects uninterruptedly. We expanded our market share for the strategic products Enstilar® and Kyntheum® and maintained our position in thrombosis, setting us up well for the anticipated market recovery in 2021. Tralokinumab is under regulatory review in the US and in Europe, and we are looking forward to launching this new treatment option for atopic dermatitis when approved in 2021. It is an important opportunity for LEO Pharma, because patients around the world need additional options. In line with our 2030 strategy which we introduced last year, we will continue to accelerate our R&D efforts to rapidly expand and diversify our portfolio in a range of dermatological indications.”
Key figures
|
DKK million |
2020 |
2019 |
∆ |
∆ LC* |
|
Revenue |
10,133 |
10,805 |
(6%) |
(4.2%) |
|
EBITDA |
521 |
(130) |
501% |
(78%) |
|
Operating profit (EBIT) |
(726) |
(1,313) |
45% |
(150%) |
|
Net profit |
(951) |
(1,287) |
26% |
N/A |
|
|
||||
|
EBITDA margin established portfolio |
32.5%* |
32.4%* |
||
|
R&D investments (% of revenue) |
21% |
23% |
||
|
|
*Change in local currencies and adjusted for divestments and other one-time effects
Annual report 2020
The full results are available in the LEO Pharma Annual Report 2020 on the company’s website at https://www.leo-pharma.com/Our-responsibility/Our-annual-reporting
Changes to LEO Pharma’s Board of Directors
At LEO Pharma’s Annual General Meeting, Lars Green of LEO Holding and The LEO Foundation was elected new member of the board. Cristina Lage and Jesper Hoejland did not stand up for re-election and will leave LEO Pharma’s Board of Directors.
- Ends -
Contacts
Henrik Kyndlev
HDTDK@leo-pharma.com
+45 3140 6180
Images

About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.
For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones16.11.2026 10:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 16 November, 2026 - In 9M 2026, LEO Pharma delivered strong innovation-led growth, with a significantly improved gross margin and continued investment in innovation. In September, LEO Pharma completed the acquisition of dersimelagon, an investigational first-in-class oral therapy now under FDA Priority Review, marking an important strategic milestone. Momentum continued after the period, with new approvals for Anzupgo® in Europe and China, further extending the product’s reach and underscoring LEO Pharma’s commitment to advancing innovation in dermatology. Financial highlights LEO Pharma’s revenue increased by 9% to DKK 10,961 million for 9M 2026, and by 11% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) with Rest of World (10% at CER) and Europe (1% at CER) also contributing. Revenue from the Dermatology portfolio grew by 13% (CER), driven by the Innovative brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China13.11.2026 08:00:00 CET | Pressemeddelelse
Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7 The approval reflects LEO Pharma’s commitment to improving care for adults living with moderate to severe chronic hand eczema in China, an exciting and important market for the company.
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
